|
News Briefs National Institutes of Health Awards Grant for Study of Cyanovirin-N as HIV-Prevention CompoundNovember 5, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Huntingdon Valley, Pa.-based Biosyn Inc. announced Monday that it and five partners -- the University of Pennsylvania, Duke University, TherImmune Research Corp., Southern Research Institute and St. George's Medical School in the United Kingdom -- have been awarded a $10 million grant from the National Institutes of Health for the development of a compound to prevent sexual transmission of HIV. In early research, Cyanovirin-N was shown to prevent vaginal and rectal transmission of simian-human immunodeficiency virus, an HIV-like virus that infects monkeys, Biosyn said. The five-year grant's funding will be used for pre-clinical development and clinical trials investigating the compound's safety and effectiveness in preventing HIV transmission. Associated Press 11.04.02 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|